Cardiac function and cardiopulmonary performance in patients
after treatment for non-Hodgkin's lymphoma

J 2006

Cardiac function and cardiopulmonary performance in patients after treatment for non-Hodgkin's lymphoma

ELBL, Lubomír, Ingrid VÁŠOVÁ, Iva TOMÁŠKOVÁ, František JEDLIČKA, Milan NAVRÁTIL et. al.

Základní údaje

Originální název

Cardiac function and cardiopulmonary performance in patients after treatment for non-Hodgkin's lymphoma

Název česky

Srdeční funkce a kardiopulmonární výkon u pacientů po léčbě non-Hodkingova lymfomu

Autoři

ELBL, Lubomír (203 Česká republika, garant), Ingrid VÁŠOVÁ (203 Česká republika), Iva TOMÁŠKOVÁ (203 Česká republika), František JEDLIČKA (203 Česká republika), Milan NAVRÁTIL (203 Česká republika), Zdeněk POSPÍŠIL (203 Česká republika) a Jiří VORLÍČEK (203 Česká republika)

Vydání

Neoplasma, SLOVAKIA, VEDA, SLOVAK ACADEMY SCIENCES, 2006, 0028-2685

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Slovensko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.247

Kód RIV

RIV/00216224:14310/06:00025786

Organizační jednotka

Přírodovědecká fakulta

UT WoS

000236399400014

Klíčová slova anglicky

cardiotoxicity; doxorubicin; non-Hodgkin's lymphoma

Štítky

cardiotoxicity, doxorubicin, non-Hodgkin's lymphoma

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 22. 6. 2009 16:18, prof. RNDr. Zdeněk Pospíšil, Dr.

Anotace

ORIG CZ

V originále

Authors conducted a one-year prospective study to determine whether CHOP regimen (cyclophosphamide, doxorubicin, vincristin, and prednisone), used in the treatment of aggressive non-Hodgkin's lymphoma, is associated with the presence of an early impairment of cardiac function. Forty seven patients were prospectively examined (27 male and 20 female) aged 49 +/- 14 years who were treated with CHOP regimen. Rest echocardiography was performed at baseline and one-year control. Cardiopulmonary exercise test was carried out at one-year control examination. The ejection fraction (EF), parameters of diastolic function, myocardial performance index (MPI), and pVO(2) were used as parameters of cardiopulmonary performance. The cumulative dose (CD) of doxorubicin was 277 +/- 56 (300 mg/m(2)) was given. The baseline EF 64 +/- 5% (64%) decreased to 58 +/- 7% (57%) at the one-year control (p<0.0001). 23% of patients exhibited a drop in EF >10% during the follow-up. 43% revealed a pathologically increased value of MPI >0.55, and 47% impaired diastolic function compared to the baseline values, respectively. 21% of patients exhibited a decrease of pVO(2) <20 ml/kg/min, and 17% pVO(2) <80% of the reference value, respectively. None of the patients developed signs of heart failure. The Doppler parameters of both diastolic and global LV function were the most affected measures and significantly influenced the cardiopulmonary performance. Multivariate analysis showed that CD >= 300 mg/m(2) (OR=8.08; p<0.05) and the presence of risk factors (OR=9.48; p<0.008) are the best predictors of cardiotoxicity. The results show that subclinical cardiac impairment was frequent in patients receiving the CHOP regimen with safe cumulative doses of doxorubicin. The value of described changes for the development of heart failure has to be assessed during the prospective follow-up.

Česky

Závěry roční prospektivní studie: režim CHOP (cyclophosphamide, doxorubicin, vincristin a prednisone) s bezpečným dávkováním doxorubicinu často způsobuje subklinické zhoršení srdeční funkce.

Návaznosti

LC06024, projekt VaV

Název: Centrum Jaroslava Hájka pro teoretickou a aplikovanou statistiku

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Centrum Jaroslava Hájka pro teoretickou a aplikovanou statistiku

Citovat

ELBL, Lubomír, Ingrid VÁŠOVÁ, Iva TOMÁŠKOVÁ, František JEDLIČKA, Milan NAVRÁTIL, Zdeněk POSPÍŠIL a Jiří VORLÍČEK. Cardiac function and cardiopulmonary performance in patients after treatment for non-Hodgkin's lymphoma. Neoplasma. SLOVAKIA: VEDA, SLOVAK ACADEMY SCIENCES, 2006, roč. 53, č. 2, s. 174-181. ISSN 0028-2685.

@article{759112,
   author = {Elbl, Lubomír and Vášová, Ingrid and Tomášková, Iva and Jedlička, František and Navrátil, Milan and Pospíšil, Zdeněk and Vorlíček, Jiří},
   article_location = {SLOVAKIA},
   article_number = {2},
   keywords = {cardiotoxicity; doxorubicin; non-Hodgkin's lymphoma},
   language = {eng},
   issn = {0028-2685},
   journal = {Neoplasma},
   title = {Cardiac function and cardiopulmonary performance in patients after treatment for non-Hodgkin's lymphoma},
   volume = {53},
   year = {2006}
}

TY  - JOUR
ID  - 759112
AU  - Elbl, Lubomír - Vášová, Ingrid - Tomášková, Iva - Jedlička, František - Navrátil, Milan - Pospíšil, Zdeněk - Vorlíček, Jiří
PY  - 2006
TI  - Cardiac function and cardiopulmonary performance in patients after treatment for non-Hodgkin's lymphoma
JF  - Neoplasma
VL  - 53
IS  - 2
SP  - 174-181
EP  - 174-181
PB  - VEDA, SLOVAK ACADEMY SCIENCES
SN  - 00282685
KW  - cardiotoxicity
KW  - doxorubicin
KW  - non-Hodgkin's lymphoma
N2  - Authors conducted a one-year prospective study to determine whether CHOP regimen (cyclophosphamide, doxorubicin, vincristin, and prednisone), used in the treatment of aggressive non-Hodgkin's lymphoma, is associated with the presence of an early impairment of cardiac function. Forty seven patients were prospectively examined (27 male and 20 female) aged 49 +/- 14 years who were treated with CHOP regimen. Rest echocardiography was performed at baseline and one-year control. Cardiopulmonary exercise test was carried out at one-year control examination. The ejection fraction (EF), parameters of diastolic function, myocardial performance index (MPI), and pVO(2) were used as parameters of cardiopulmonary performance. The cumulative dose (CD) of doxorubicin was 277 +/- 56 (300 mg/m(2)) was given. The baseline EF 64 +/- 5% (64%) decreased to 58 +/- 7% (57%) at the one-year control (p<0.0001). 23% of patients exhibited a drop in EF >10% during the follow-up. 43% revealed a pathologically increased value of MPI >0.55, and 47% impaired diastolic function compared to the baseline values, respectively. 21% of patients exhibited a decrease of pVO(2) <20 ml/kg/min, and 17% pVO(2) <80% of the reference value, respectively. None of the patients developed signs of heart failure. The Doppler parameters of both diastolic and global LV function were the most affected measures and significantly influenced the cardiopulmonary performance. Multivariate analysis showed that CD >= 300 mg/m(2) (OR=8.08; p<0.05) and the presence of risk factors (OR=9.48; p<0.008) are the best predictors of cardiotoxicity. The results show that subclinical cardiac impairment was frequent in patients receiving the CHOP regimen with safe cumulative doses of doxorubicin. The value of described changes for the development of heart failure has to be assessed during the prospective follow-up.
ER  -

ELBL, Lubomír, Ingrid VÁŠOVÁ, Iva TOMÁŠKOVÁ, František JEDLIČKA, Milan NAVRÁTIL, Zdeněk POSPÍŠIL a Jiří VORLÍČEK. Cardiac function and cardiopulmonary performance in patients after treatment for non-Hodgkin's lymphoma. \textit{Neoplasma}. SLOVAKIA: VEDA, SLOVAK ACADEMY SCIENCES, 2006, roč.~53, č.~2, s.~174-181. ISSN~0028-2685.

Podrobný výpis o publikaci